ELIAS Animal Health is a medical biotechnology company bringing a new treatment for cancer to the veterinary sector with an initial focus on cancer in dogs. Our novel therapeutic approach offers the promise improved clinical outcomes and quality of life for cancer patients. ELIAS is commercializing a personalized treatment platform called ELIAS Cancer Immunotherapy that is built upon 50+ years of intensive scientific and medical research into the interactions between cancer and the immune system. ECI utilizes a proprietary and patented combination of cancer vaccination pretreatment and ex vivo activated "killer" T cell immunotherapy that triggers the patient's own immune system to kill cancer cells. This dual approach is what makes ECI distinct and offers the promise of improved outcomes and better quality of life for cancer patients. Clinical studies have been conducted in appendicular osteosarcoma and B cell lymphoma. Additional clinical studies are planned in other cancer types, including transitional cell carcinoma and hemangiosarcoma. The ELIAS Cancer Immunotherapy will commercially available for the treatment of dogs diagnosed with osteosarcoma at several locations throughout the United States by late 2018..
10900 S. Clay Blair Blvd.
Olathe, Kansas 66061